Table 3 Comparison of univariate and multivariate Cox proportional hazards analyses of progression-free survival and cancer-specific survival in MCM4 expression and other molecules

MCM4

 Negative

1 (Reference)

0.0366

1 (Reference)

0.3838

1 (Reference)

0.0022

1 (Reference)

0.0090

 Positive

3.76 (1.24–16.22)

1.80 (0.48–6.74)

5.19 (2.01–17.60)

5.07 (1.73–21.62)

Ki-67

 Negative

1 (Reference)

0.0841

1 (Reference)

0.1166

 Positive

2.27 (0.87–5.76)

1.82 (0.83–3.78)

PD-L1 in TCs

 Negative

1 (Reference)

0.0012

1 (Reference)

0.2213

1 (Reference)

0.0093

1 (Reference)

0.2009

 Positive

4.82 (1.86–12.49)

2.10 (0.64–6.94)

2.97 (1.31–6.76)

1.85 (0.72–4.77)

PD-L1 in TILs

 Negative

1 (Reference)

0.0073

1 (Reference)

0.1003

1 (Reference)

0.3858

 Positive

3.58 (1.41–9.10)

2.62 (0.83–8.26)

1.40 (0.65-3.00)

CD44v9

 Negative

1 (Reference)

0.0400

1 (Reference)

0.1258

1 (Reference)

0.0155

1 (Reference)

0.0132

 Positive

3.03 (1.00-8.73)

2.33 (0.79–6.86)

2.78 (1.17–6.27)

2.87 (1.20–6.51)

HER2

 Negative

1(Reference)

0.8354

1(Reference)

0.6696

 Positive

1.14 (0.33–3.94)

1.25 (0.44–3.61)

EGFR

 Negative

1(Reference)

0.3310

1(Reference)

0.1024

 Positive

1.63 (0.61–4.34)

1.89 (0.88–4.03)

FGFR3

 Negative

1(Reference)

0.1954

1(Reference)

0.3400

 Positive

0.44 (0.13–1.52)

0.66 (0.28–1.54)

p53

 Negative

1 (Reference)

0.3782

1 (Reference)

0.2433

 Positive

1.55 (0.54–4.01)

1.57 (0.70–3.29)